However, advanced diseases castration-resistant prostate cancer are often treated with hormone therapy, and androgen suppression can alter the PSMA expression, thus limiting the capability of PSMA-PET/CT to correctly identify the metastasis and limiting the capability of this modality to assess response to therapy.12 This evidence concerns the gene FOLH1 and prostate cancer.